HHighlight Therapeutics — Series B (estimated) · €15M
Valencia-based Highlight Therapeutics closed a €15M round led by Buenavista Equity Partners through its BV Healthcare Growth Innvierte I fund, created with Columbus Venture Partners. The money funds the Phase 2b trial of BO-112, an intratumoral immunotherapy for basal cell carcinoma originally discovered at Spain's CNIO in 2009.
LeadBuenavista Equity Partners
RoundSeries B (estimated)
Announced16 Sep 2025
CityValencia
SectorHealthtech & Bio · Biotech / Immuno-oncology
Source
W
C
W
C
